Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.

ABSTRACT:

Background

Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness remains limited. This study evaluates treatment responses and clinical factors influencing T-VEC outcomes in patients with diverse treatment histories.

Methods

We analyzed patients with metastatic melanoma treated with T-VEC between 2015 and 2024. Objective responses (OR), complete response (CR) and partial response were assessed using univariate and multivariate Cox regression models. Durability of responses, progression-free survival (PFS), and overall survival (OS) were evaluated using Kaplan-Meier estimates.

Results

SUBMITTER: Yamada MM 

PROVIDER: S-EPMC12742145 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature